Insights

Loading spinner
Gathering insights about AbilityPharma

AbilityPharma Tech Stack

AbilityPharma uses 8 technology products and services including Open Graph, Google Workspace, Font Awesome, and more. Explore AbilityPharma's tech stack below.

  • Open Graph
    Content Management System
  • Google Workspace
    Email
  • Font Awesome
    Font Scripts
  • FancyBox
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • Google Analytics
    Web Analytics
  • Apache
    Web Servers
  • Apache HTTP Server
    Web Servers

Media & News

AbilityPharma's Email Address Formats

AbilityPharma uses at least 1 format(s):
AbilityPharma Email FormatsExamplePercentage
First.Last@abilitypharma.comJohn.Doe@abilitypharma.com
33%
First.Middle@abilitypharma.comJohn.Michael@abilitypharma.com
32%
First.Last@abilitypharma.comJohn.Doe@abilitypharma.com
2%
First.Last@abilitypharma.comJohn.Doe@abilitypharma.com
33%

Frequently Asked Questions

Where is AbilityPharma's headquarters located?

Minus sign iconPlus sign icon
AbilityPharma's main headquarters is located at 3 Avinguda Parc Tecnològic Cerdanyola Del Valles, Catalonia 08290 Spain. The company has employees across 2 continents, including EuropeNorth America.

What is AbilityPharma's phone number?

Minus sign iconPlus sign icon
You can contact AbilityPharma's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is AbilityPharma's official website and social media links?

Minus sign iconPlus sign icon
AbilityPharma's official website is abilitypharma.com and has social profiles on LinkedInCrunchbase.

What is AbilityPharma's SIC code NAICS code?

Minus sign iconPlus sign icon
AbilityPharma's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AbilityPharma have currently?

Minus sign iconPlus sign icon
As of February 2026, AbilityPharma has approximately 23 employees across 2 continents, including EuropeNorth America. Key team members include Chief Business Officer: D. S.Chief Operating Officer: H. P. M.Vp Clinical & Regulatory Affairs: G. F. D.. Explore AbilityPharma's employee directory with LeadIQ.

What industry does AbilityPharma belong to?

Minus sign iconPlus sign icon
AbilityPharma operates in the Biotechnology Research industry.

What technology does AbilityPharma use?

Minus sign iconPlus sign icon
AbilityPharma's tech stack includes Open GraphGoogle WorkspaceFont AwesomeFancyBoxjQueryGoogle AnalyticsApacheApache HTTP Server.

What is AbilityPharma's email format?

Minus sign iconPlus sign icon
AbilityPharma's email format typically follows the pattern of First.Last@abilitypharma.com. Find more AbilityPharma email formats with LeadIQ.

When was AbilityPharma founded?

Minus sign iconPlus sign icon
AbilityPharma was founded in 2009.

AbilityPharma

Biotechnology ResearchCatalonia, Spain11-50 Employees

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. 

AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel.

ABTL0812  has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard).

ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic.

The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. 

ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. 

Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

Section iconCompany Overview

Headquarters
3 Avinguda Parc Tecnològic Cerdanyola Del Valles, Catalonia 08290 Spain
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
11-50

Section iconFunding & Financials

  • $1M$10M

    AbilityPharma's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    AbilityPharma's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.